RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)
NCT00830895 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49
Last updated 2022-11-09
Summary
To assess the efficacy and safety of RAD001 (everolimus) in non-clear cell renal cell carcinoma
Conditions
Interventions
- DRUG
-
RAD001
RAD001 10mg/day
Sponsors & Collaborators
-
Seoul National University Hospital
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-01-31
- Primary Completion
- 2010-10-31
- Completion
- 2012-12-31
Countries
- South Korea
Study Locations
More Related Trials
-
Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
NCT01715935 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib and RAD001 Renal Cell Carcinoma
NCT00384969 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
NCT01206764 ·Status: COMPLETED ·Phase: PHASE4
-
Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
NCT03013335 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
NCT01514448 ·Status: COMPLETED ·Phase: PHASE4
-
Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00331409 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma
NCT00422344 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma
NCT00059735 ·Status: COMPLETED ·Phase: PHASE2
-
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
NCT00392821 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
NCT02089334 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy
NCT00655252 ·Status: NO_LONGER_AVAILABLE
-
A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma
NCT00788060 ·Status: COMPLETED ·Phase: PHASE1
-
Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal
NCT00831480 ·Status: TERMINATED ·Phase: PHASE2
-
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
NCT01120249 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
NCT00651482 ·Status: TERMINATED ·Phase: PHASE2
-
Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
NCT01266837 ·Status: COMPLETED ·Phase: PHASE4
-
A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
NCT02915783 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
NCT00719264 ·Status: COMPLETED ·Phase: PHASE2
-
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
NCT05188118 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
NCT05124431 ·Status: UNKNOWN ·Phase: PHASE2
-
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
NCT01354431 ·Status: COMPLETED ·Phase: PHASE2
-
Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer
NCT01888042 ·Status: TERMINATED ·Phase: PHASE2
-
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
NCT02724020 ·Status: COMPLETED ·Phase: PHASE2
-
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
NCT06211790 ·Status: RECRUITING ·Phase: PHASE2
-
Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure
NCT07117409 ·Status: TERMINATED